Samuel Bogoch

Learn More
The serum anti-malignin antibody (AMA) test determines the antibody to malignin, a 10,000-Da peptide present in patients with a wide variety of cancers. A total of 3315 double-blind tests demonstrated that AMA is a general transformation antibody, elevated in active nonterminal cancer, regardless of the site or tissue type, with sensitivity and specificity(More)
extractability of phylloerythrin from bile was tested by adding fresh ox bile to equal volumes of buffer solutions and shaking with ether. In solutions below pH 5 almost all the phylloerythrin was extracted into the ether. Above pH 7-5 less than 5% of the phylloerythrin was present in the ether phase. Between pH 5 and 7-5 intermediate values were obtained.(More)
Human antimalignin antibody (AMA) appears to have clinical significance because in actuarial studies its concentration relates quantitatively to survival (Bogoch et al. Protides Biol Fluids 1984; 31:739-747). Therefore isolation, characterization, and production in vitro of AMA were undertaken. Serum AMA concentrations are elevated in cancer, regardless of(More)
By reference to a "checklist" of requirements for substances or processes to qualify as surrogate endpoint biomarkers, both malignin and antimalignin antibody are found to be suitable for use in breast cancer chemoprevention trials. Antimalignin has been shown to be highly specific and sensitive, modulatable and reversible, detectable early in appearance of(More)